DeepMed Research

IPSEN, OOO

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1929-01-01

Employees: 5.7K

Market Cap: $9.8B

Website: https://www.ipsen.com/

Clinical Trials

Cabozantinib Real-life Use for Advanced Renal Cell Carcinoma in France: a Retrospective Descriptive Non-interventional Study of 2 Cohorts.

Completed

Conditions: Renal Cell Carcinoma

First Posted Date: 2018-11-16

Last Posted Date: 2019-07-26

Lead Sponsor: Ipsen

Target Recruit Count: 450

Registration Number: NCT03744585

Locations: 🇫🇷
Ipsen Central Contact, Paris, France

Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC

Completed

Conditions: Renal Cell Carcinoma Metastatic
Renal Cell Carcinoma

First Posted Date: 2018-10-09

Last Posted Date: 2019-08-28

Lead Sponsor: Ipsen

Target Recruit Count: 28

Registration Number: NCT03699579

Locations: 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
🇨🇳
National Taiwan University Hospital, Taipei, Taiwan

Define the Optimal Uptake Time of 68Ga-OPS202 When Used as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Newly Diagnosed Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Satoreotide trizoxetan

First Posted Date: 2018-10-05

Last Posted Date: 2020-09-07

Lead Sponsor: Ipsen

Target Recruit Count: 4

Registration Number: NCT03697551

Locations: 🇦🇹
Medical University Innsbruck, Innsbruck, Austria

A Non-interventional Retrospective Study to Describe Early Clinical Experience With Cabozantinib in Patients With Advanced Renal Cell Carcinoma (RCC) in the UK

Completed

Conditions: Advanced Renal Cell Carcinoma

First Posted Date: 2018-10-04

Last Posted Date: 2020-11-05

Lead Sponsor: Ipsen

Target Recruit Count: 108

Registration Number: NCT03696407

Locations: 🇬🇧
Royal Sussex County Hospital, Brighton, United Kingdom
🇬🇧
Addenbrooke's Hospital, Cambridge, United Kingdom
🇬🇧
Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

and more 3 locations

Study of the Effectiveness of ETIASA® (Sustained Release 5-Aminosalicylate) in Maintenance Treatment of Ulcerative Colitis (UC)

Completed

Conditions: Ulcerative Colitis

First Posted Date: 2018-09-28

Last Posted Date: 2021-02-02

Lead Sponsor: Ipsen

Target Recruit Count: 607

Registration Number: NCT03689673

Locations: 🇨🇳
Nanfang Hospital of Southern Medical University, Guangzhou, China
🇨🇳
Union Hospital Affiliated to Tongji Medical College, Wuhan, China
🇨🇳
China-Japan Union Hospital of Jilin University, Changchun, China

and more 23 locations

Dysport in Post-Surgical Neuralgia

Phase 2

Completed

Conditions: Chronic Scar Pain

Interventions: Drug: Lidocaine
Biological: Botulinum toxin type A
Drug: Placebo

First Posted Date: 2018-09-10

Last Posted Date: 2021-01-12

Lead Sponsor: Ipsen

Target Recruit Count: 16

Registration Number: NCT03663101

Locations: 🇬🇧
St Pancras Clinical Research, London, United Kingdom

Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.

Recruiting

Conditions: Advanced Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma

First Posted Date: 2018-08-27

Last Posted Date: 2025-04-30

Lead Sponsor: Ipsen

Target Recruit Count: 210

Registration Number: NCT03647878

Locations: 🇦🇹
Landeskrankenhaus Hochsteiermark, Leoben, Austria
🇦🇹
Ordensklinikum Linz GmbH, Linz, Austria
🇦🇹
Kepler Universitätsklinikum GmbH, Linz, Austria

and more 79 locations

Dysport in Vulvodynia Phase II Study

Phase 2

Terminated

Conditions: Vulvodynia

Interventions: Drug: Placebo
Biological: Botulinum toxin type A

First Posted Date: 2018-07-26

Last Posted Date: 2021-12-09

Lead Sponsor: Ipsen

Target Recruit Count: 60

Registration Number: NCT03598777

Locations: 🇺🇸
Seattle Women's: Health, Research, Gynecology®, Seattle, Washington, United States
🇺🇸
The Center for Vulvovaginal Disorders, New York, New York, United States
🇺🇸
New Age Medical Research Corporation, Miami, Florida, United States

and more 5 locations

Study of Diphereline 3.75 mg Treatment In Women Suffering From Internal Genital Endometriosis

Completed

Conditions: Internal Endometriosis

First Posted Date: 2018-07-13

Last Posted Date: 2018-07-13

Lead Sponsor: Ipsen

Target Recruit Count: 465

Registration Number: NCT03586063

Locations: 🇷🇺
Scientific center of Family Health Problems and Human reproduction of Siberian branch of RAMS, Irkutsk, Russian Federation
🇷🇺
SEI Irkutsk State medical refresher institute, Irkutsk, Russian Federation
🇷🇺
City hospital #2, Krasnodar multi-field medical diagnostic association, endoscopic gynecology center, Krasnodar, Russian Federation

and more 31 locations

Dysport in Hallux Abducto Valgus (HAV) Phase IIa

Phase 2

Completed

Conditions: Hallux Abducto Valgus

Interventions: Biological: Botulinum toxin type A
Drug: Placebo

First Posted Date: 2018-06-26

Last Posted Date: 2021-07-02

Lead Sponsor: Ipsen

Target Recruit Count: 186

Registration Number: NCT03569098

Locations: 🇺🇸
NEA Baptist Clinic, Jonesboro, Arkansas, United States
🇺🇸
Foot and Ankle Clinic, Los Angeles, California, United States
🇺🇸
Ankle and Foot Care Centers, Youngstown, Ohio, United States

and more 26 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy